Veracyte (VCYT) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01Our financial results currently depend mainly on sales of our Decipher Prostate and Afirma tests, and we may not generate sufficient revenue from these and our other diagnostic tests to grow our business
2. 02If we are unable to grow sales of our tests or products, or we are unable to launch or commercialize our new tests or products, our business may suffer
3. 03We have incurred losses in the past, we could incur net losses in the future and we may not sustain our level of profitability in the future
4. 04We depend on a few payers for a significant portion of our revenue; if one or more significant payers stops providing reimbursement or decreases the amount of reimbursement for our tests, our revenue could decline
5. 05coverage articles for Afirma, Decipher Prostate and our other tests could have an adverse effect on our business, financial condition and results of operations
6. 06If payers do not provide reimbursement, rescind or modify their reimbursement policies, delay payments for our tests, recoup past payments, or if we are unable to successfully negotiate additional reimbursement contracts, our commercial success could be compromised
7. 07We may experience limits on our revenue if physicians decide not to order our tests
8. 08We may experience limits on our revenue if patients decide not to use our tests as a result of increased costs, fees or changing payer policies
9. 09If we fail to comply with federal and state licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business
10. 10We must successfully integrate our acquired businesses, such as C2i, to realize the strategic or financial goals that we currently anticipate
11. 11Our future success and international growth depend, in part, on our ability to adapt, manufacture and distribute our tests as IVD tests
12. 12If we do not manage inventory in an effective and efficient manner, it could adversely affect our results of operations
13. 13The revenue that we have experienced in our biopharma and other services business may not continue to transpire
14. 14replacements or transition to alternative suppliers or service providers, which may materially impact our ability to generate revenue
15. 15We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy
16. 16If we are unable to support demand for our tests, products or services, our business could suffer
17. 17In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for our tests
18. 18Under previous Medicare billing rules, hospitals were required to bill for our molecular pathology tests when performed on Medicare beneficiaries who were hospital outpatients at the time of tissue specimen collection when these tests were ordered less than 14 days following the date of the patient's discharge
19. 19This change does not apply to tests performed on specimens collected from hospital inpatients. We will continue to bill hospitals for tests performed on specimens collected from hospital inpatients when the test was ordered less than 14 days after the date of discharge
20. 20If the FDA or foreign authorities regulate those of our tests that they do not currently regulate, we could incur substantial costs and delays associated with trying to obtain premarket clearance, approval or certification
21. 21Obtaining marketing authorization or certification by the FDA and foreign regulatory authorities or notifying regulatory bodies for our diagnostic tests will take significant time and require significant research, development and clinical study expenditures and ultimately may not succeed
22. 22If we are unable to obtain marketing authorizations or certifications, approvals, clearances or certifications to market Prosigna or our other IVD assays or if regulatory limitations are placed on our diagnostic kit products, our business and growth will be harmed
23. 23indications. We cannot guarantee that the regulatory authorization or certification for Prosigna or other tests will be granted or, if granted, will not be revoked, which could adversely impact our business, financial condition, and operations
24. 24We are subject to ongoing and increasingly extensive regulatory requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business
25. 25We operate in a highly competitive market. Growing understanding of the importance of biomarkers linked with therapy selection, response and early screening is leading to more companies offering services in genomic profiling which may lead to increased competition for our tests
26. 26In addition, competitors may develop their own versions of our solutions in other countries that we may seek to enter where we do not have patents or where our intellectual property rights are not recognized. Additionally, competitors could encourage the use of their solutions by physicians in other countries
27. 27We depend on our senior management team, and the loss of one or more of our executive officers, or any inability to attract and retain highly-skilled employees and other key personnel in our highly competitive industry, could adversely affect our business
28. 28Billing for our diagnostic tests is complex, and we must dedicate substantial time and resources to the billing process in order to collect cash and be paid
29. 29If our internal sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenue could be diminished
30. 30Developing, commercializing and gaining reimbursement for new products involves a lengthy and complex process, and if we do not achieve our projected development, commercialization and reimbursement goals in the timeframes we announce and expect, our business may suffer, and our stock price may decline
31. 31If we are unable to develop products to keep pace with rapid technological, medical and scientific change, our operating results and competitive position could be harmed
32. 32Complying with numerous statutes and regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties
33. 33If we use hazardous materials in a manner that causes contamination, infection or injury, we could be liable for resulting damages
34. 34Aspects of our international business expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States
35. 35We have operations located in Israel, and conflict in the Middle East and any additional escalations of hostilities may cause interruption or suspension of this site without warning, or otherwise negatively impact the global economy or our business
36. 36Our reliance on distributors for sales of our products outside of the United States, and on clinical laboratories for delivery of Prosigna testing services, could limit or prevent us from selling our products and impact our revenue
37. 37Errors or defects in our products or services could harm our reputation, decrease market acceptance of our products or services or expose us to product liability claims, and we could face substantial liabilities that exceed our resources
38. 38Issues relating to the use of AI and machine learning in our offerings could adversely affect our business and operating results
39. 39Security breaches, loss of data and other disruptions to our or our third-party service providers' data systems could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation
40. 40Risks associated with data privacy issues, including evolving laws, regulations and associated compliance efforts, may adversely impact our business and financial results
41. 41Hampshire, New Jersey, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia have each enacted laws similar to the CCPA/CPRA. The multiple layers of privacy law within the United States could increase our potential liability, increase our compliance costs, and adversely affect our business
42. 42If we are unable to protect our intellectual property effectively, our business may be harmed
43. 43not provide us with any competitive advantages. It is possible that others will design around our current or future patented technologies
44. 44relevant parties, or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If we are required to assert our rights against such parties, it may result in significant cost and distraction
45. 45If we are unable to enforce or defend our intellectual property effectively, our business may be harmed
46. 46If we cannot license or maintain rights to use technologies on reasonable terms, our business may suffer
47. 47party’s technology, we often agree to pay the licensor royalties based on sales of our solutions. Royalties are a component of cost of revenue and affect the margins on our solutions
48. 48We may be involved in litigation related to third party intellectual property, which may be time-intensive and costly and may adversely affect our business, operating results or financial condition
49. 49With respect to trademarks, infringement litigation or threats of infringement litigation may require us to re-brand our product
50. 50Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us

Risks Related to Being a Public Company

1. 51If we are unable to maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected

Risks Related to Our Common Stock

1. 52Our stock price may be volatile, and you may not be able to sell shares of our common stock at or above the price you paid
2. 53Anti-takeover provisions in our charter documents and under Delaware law could discourage, delay or prevent a change in control and may affect the trading price of our common stock
3. 54We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future
4. 55Our operating results may be adversely affected by unfavorable macroeconomic and market conditions
5. 56Our business and the operations of our laboratories and manufacturing sites are subject to the risk of disruptions caused by pandemics, political events, war, terrorism, earthquakes, fire, power outages, severe weather, floods, and other catastrophic events
6. 57We are exposed to risks associated with transactions denominated in foreign currency
7. 58We may be unable to raise additional capital on acceptable terms in the future, which could limit our ability to develop and commercialize new solutions and technologies and expand our operations, organically or inorganically
8. 59Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued
9. 60Impairment in the value of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition
10. 61Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating results
11. 62Our consolidated financial statements are subject to change and if our estimates or judgments relating to our critical accounting policies prove to be incorrect, our operating results could be adversely affected
12. 63Investors’ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks